Recruiting Studies

 

– Multiple Sclerosis –

 Biogen 109MS401 RRMS (ESTEEM)

A Multicenter, Global, Observational Study to Collect Information on Safety and to Document the Drug Utilization of Tecfidera™ (Dimethyl Fumarate) When Used in Routine Medical Practice in the Treatment of Multiple Sclerosis (ESTEEM)

 Novartis CFT2403 RRMS (PASSAGE)

Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies (PASSAGE)

Sanofi OBS13434 (PASS)

A prospective, multicenter, observational post-authorization safety study to evaluate the long term safety profile of lemtrada® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis

Sanofi OBS14448 (PRO-ACT)

A Prospective, 24-Month Observational Study to Evaluate Patient Reported Outcomes and Safety After LEMTRADA® Treatment In Patients With Relapsing Multiple Sclerosis Switching From A Prior Disease Modifying Therapy

Genentech MN30035 (CHORDS)

An open-label study to evaluate the effectiveness and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have had a suboptimal response to an adequate course of disease modifying treatment

Genentech ML29966 (OBOE)

An open-label, multicenter, biomarker study to explore the mechanism of action of ocrelizumab and B-cell biology in patients with relapsing multiple sclerosis


– Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders –


– Amyotrophic Lateral Sclerosis –

Biogen 233AS101

A Phase 1, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB067 Administered to Adult Subjects with Amyotrophic Lateral Sclerosis

CALS-NIC

Observational, longitudinal MRI study for ALS (recruiting both ALS patients & age/sex matched healthy controls) Please contact kristiana.salmon@mcgill.ca

Biogen 999AS003

Methodology Study of Novel Electrophysiological, Physical, and Imaging Outcome Measures to Assess the Progression of Amyotrophic Lateral Sclerosis


– Brain Tumor –

BMS CA209-498

A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

BMS CA209-548

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6-methylguanine DNA methyltransferase) Glioblastoma

Ethicon EVICEL BIOS-14-002

A Single-Blinded, Randomized, Controlled Study to Evaluate the Safety and Effectiveness of EVICEL® Fibrin Sealant (Human) Compared to a Hydrogel Sealant as an Adjunct to Sutured Dural Repair

ImmunoCellular Therapeutics ICT-107-301 (STING)

Study of Immunotherapy in Newly Diagnosed Glioblastoma: A Phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy

  — Brain Tumour Studies at the MUHC  — (not coordinated by the CRU)

A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy followed by Adjuvant Sunitinib and Temozolomide for Newly Diagnosed Glioblastoma Patients with an Unmethylated MGMT Gene Promoter. Principal Investigator: Bassam Abdulkarim Phone: 514-934-1934, x43594 (MGH) Email: bassam.abdulkarim@mcgill.ca

RTOG 0925 – Natural History of Postoperative Cognitive Function, Quality of Life, and Seizure Control in Patients With Supratentorial Low-Risk Grade II Glioma Principal Investigator: Kevin Petrecca Phone: (514)398-2591 (Secretary – Susan) Email: kevin.petrecca@mcgill.ca


 — Migrane –

Allergan PREDICT

Patient Reported Outcomes in Patients With Chronic Migraine Treated With BOTOX®


 — Post-polio –

Grifols IG1104 post-polio syndrome:

A Multicenter, Prospective, Randomized, Placebo-controlled, Double-blind, Parallel‑Group Clinical Trial to Assess the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma 5% DIF in Patients With Post-Polio Syndrome


– Neuromuscular – 

Baxalta 161403

A Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) and Immune Globulin Infusion (Human), 10% (GAMMAGARD LIQUID/KIOVIG) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

Genzyme Pompe (disease registry)

UCI IPANEMA

Investigating Pompe Prevalence in NEuromuscular Medicine Academic Practices (IPANEMA Study)

Novartis CFZ533X2204

A multi-center, randomized, double-blind, placebo-controlled, parallel group study to preliminarily evaluate the safety, tolerability, pharmacokinetics and efficacy of CFZ533 in patients with moderate to severe myasthenia gravis

Grifols GTI1305 myasthenia gravis

A multicenter, prospective, open-label, non-controlled clinical trial to assess the efficacy and safety of lmmune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in patients with Myasthenia Gravis exacerbations


 — Stroke –

MISTIE III stroke

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III


 — Super-Refractory Status Epilepticus –

SAGE-547

An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus


– Parkinson –

AbbVie CADENCE

Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence


 — Alzheimer’s disease and Dementia –

Biogen 221AD301

A Phase 3 Multicenter, Randomized, Double-blind, Placeb0-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects with Early Alzheimer’s Disease

Centre de recherche de l’IUGM

Quantitative Magnetic Resonance Imaging of oxygen transport: a new window on mitochondrial dysfunction in Alzheimer’s disease, Phase 3: data acquisition in individuals affected by Alzheimer’s disease and demographically-matched control participants.

GENFI

Genetic Frontotemporal Dementia Initiative (GENFI)

CHARMED

Prospective Study of Single Subject Cortical Thickness as an Early Diagnostic Biomarker of Frontotemporal Dementia


– Spine Surgery –

Pfizer B3451002

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Staphylococcus Aureus 4-Antigen Vaccine (Sa4ag) in Adults Undergoing Elective Posterior Instrumented Lumbar Spinal Fusion Procedures

AOSpine CSM-Protect

Efficacy of Riluzole in Patients With Cervical Spondylotic Myelopathy Undergoing Surgical Treatment. A Randomized, Double-Blind, Placebo-controlled Multi-Center Study